Australia's most trusted source of pharma news
Saturday, 13 February 2016
Lost Your Access?
Mylan finally bags Meda
Alphapharm owner Mylan has persuaded Swedish generics maker Meda into a $14 billion takeover after two previous attempts.
Cracks in chemo fee arrangements
A proposed model to make all efficient funding of chemotherapy payments directly to compounders is 'unworkable', according to stakeholders.
TGA delays PrEP decision
The Greens are again calling on the government to expedite access to Gilead's
for use as pre-exposure HIV prophylaxis after the TGA revealed consideration has been delayed for another two months.
Consumers cautious about IVF a-flag
The PBAC needs to consider the brand-specific training that goes into prescribing and using infertility treatments when deciding whether to a-flag Finox's follitropin alfa biosimilar to Merck's
, says consumer group Access Australia.
Has MA done enough to scare Ley?
The list of dire predictions for health and innovation that MA makes in its pre- budget submission should be enough to scare anybody - except maybe Sussan Ley.
Many more job losses to come: MA
The axe will soon fall on another 150 pharma jobs, continuing on from the more than 100 losses late last year, Medicines Australia says in its pre-budget submission to government.
PBS prices should be lower govt told
The government has been told it should toughen negotiation 'to purchase pharmaceuticals at more competitive prices'.
Rheumatologists 'on back foot' with Inflectra data
The Australian Rheumatology Association is hopeful a data collection program around the use of biosimilar infliximab will happen soon, though it is "not a done deal", its president says.
Inflectra gains foothold despite Remicade discounting
Australia is beginning to see discounting similar to other jurisdictions as Pfizer and Janssen battle for the infliximab market in hospitals.
GPs OK'd to write new hep C scripts
GPs will not need to be accredited to be able to write scripts for the new hepatitis C drugs set to list on the PBS next month.
PBS de-listings: govt was misleading
Health Department officials were put under pressure over the de-listing of
at last night's Senate Estimates hearings as the government was accused of misleading the public over costs.
New boss for Baxter ANZ
Baxter Healthcare has appointed Steven Flynn as its new general manager for Australia and New Zealand.
Guild confident of PBAC paracetamol review
The Guild is 'quietly confident' that the PBAC will review the de-listing of paracetamol osteo, executive director David Quilty has said.
TGA still pondering Xarelto's fate
The TGA says it will take into account EMA conclusions as it considers the implications of doubts surrounding a pivotal trial that backed registration of Bayer's
Time to support biosimilars
Biosimilars will play an important role in the PBS system and industry needs to support an evidence-based role for these medicines, rather than seeking to restrict their uptake says regulatory expert.
AZ scores cancer win, lays out more pipeline
Lung cancer drug Tagrisso has been given the go-ahead in Europe while four new treatments are on the way to filing says pharma giant AZ.
Networking: how to do it better
Love it or hate it, networking is an essential part of many jobs. The good news is, if you find it awkward, it's not so hard to improve.
New registrations in asthma and cholesterol
The TGA has granted registration for GSK's new asthma biological and for another wave of cholesterol lowering generics.
OTC sector looks for opportunities from reform
Lindsay Forrest, newly anointed chair of the Australian Self Medication Industry, speaks to
Pharma in Focus
on opportunities and problems facing the OTC sector in 2016.
Events & Conferences
© 2003 - 2016 Lush Media
Pharma in Focus
Jolly Good Design